A vs ILMN
Agilent Technologies and Illumina, Inc., both Healthcare
Agilent Technologies is the larger company at $36B against $27B. On trailing earnings A is the cheaper of the two at a P/E of 33.6 against 51.9, a gap that is only a bargain if the two are growing at similar rates. Over the past year ILMN returned +171% against +34% for A. The RyuScore puts A ahead, 70 against 36 out of 100.
| Figure | A | ILMN |
|---|---|---|
| Last close | $170 | $278 |
| Market cap | $36B | $27B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | 33.6 | 51.9 |
| Dividend yield | 0.6% | n/a |
| 1-year return | +34% | +171% |
| 5-year return | +2.4% | -36% |
| RyuScoresector-relative, 1–10 | 70/100 | 36/100 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
Agilent Technologies
Revenue of $1.9B in Q3 2026, net income $362M. Its largest reported line is Life Sciences And Diagnostics Markets, 48% of the disclosed total.
Illumina, Inc.
Revenue of $1.2B in Q2 2026, net income $207M. Its largest reported line is United States And Canada, 56% of the disclosed total.
Open these two in the interactive comparison to add more names, change the period or see the correlation.